These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36724310)

  • 1. Insulin Pump-Associated Adverse Events: A Qualitative Descriptive Study of Clinical Consequences and Potential Root Causes.
    Estock JL; Codario RA; Keddem S; Zupa MF; Rodriguez KL; DiNardo MM
    Diabetes Technol Ther; 2023 May; 25(5):343-355. PubMed ID: 36724310
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetes Care; 2015 Apr; 38(4):716-22. PubMed ID: 25776138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin Pump Alarms During Adverse Events: A Qualitative Descriptive Study.
    Estock JL; Codario RA; Zupa MF; Keddem S; Rodriguez KL
    J Diabetes Sci Technol; 2023 Oct; ():19322968231209999. PubMed ID: 37905930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetologia; 2015 May; 58(5):862-70. PubMed ID: 25784563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Insulin Pump-Related Adverse Events: Potential Root Causes and Impact of the COVID-19 Pandemic.
    Orbell SL; Codario RA; Zupa MF; Estock JL
    J Diabetes Sci Technol; 2024 May; ():19322968241254521. PubMed ID: 38804542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type.
    Ross P; Gray AR; Milburn J; Kumarasamy IM; Wu F; Farrand S; Armishaw J; Wiltshire E; Rayns J; Tomlinson P; Wheeler BJ
    Acta Diabetol; 2016 Dec; 53(6):991-998. PubMed ID: 27585938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric use of insulin pump technology: a retrospective study of adverse events in children ages 1-12 years.
    Cope JU; Samuels-Reid JH; Morrison AE
    J Diabetes Sci Technol; 2012 Sep; 6(5):1053-9. PubMed ID: 23063031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimization of Hypoglycemia as an Adverse Event During Insulin Infusion: Further Refinement of the Yale Protocol.
    Marvin MR; Inzucchi SE; Besterman BJ
    Diabetes Technol Ther; 2016 Aug; 18(8):480-6. PubMed ID: 27257910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study.
    Charleer S; De Block C; Nobels F; Radermecker RP; Lowyck I; Mullens A; Scarnière D; Spincemaille K; Strivay M; Weber E; Taes Y; Vercammen C; Keymeulen B; Mathieu C; Gillard P;
    Diabetes Care; 2020 Dec; 43(12):3016-3023. PubMed ID: 33067260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.
    Ly TT; Nicholas JA; Retterath A; Lim EM; Davis EA; Jones TW
    JAMA; 2013 Sep; 310(12):1240-7. PubMed ID: 24065010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
    Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adolescent use of insulin and patient-controlled analgesia pump technology: a 10-year Food and Drug Administration retrospective study of adverse events.
    Cope JU; Morrison AE; Samuels-Reid J
    Pediatrics; 2008 May; 121(5):e1133-8. PubMed ID: 18450857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes.
    Karges B; Schwandt A; Heidtmann B; Kordonouri O; Binder E; Schierloh U; Boettcher C; Kapellen T; Rosenbauer J; Holl RW
    JAMA; 2017 Oct; 318(14):1358-1366. PubMed ID: 29049584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise.
    Danne T; Tsioli C; Kordonouri O; Blaesig S; Remus K; Roy A; Keenan B; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2014 Jun; 16(6):338-47. PubMed ID: 24447074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Basal Insulin Suspension at the Start of Exercise on Blood Glucose Levels During Continuous Versus Circuit-Based Exercise in Individuals with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion.
    Zaharieva D; Yavelberg L; Jamnik V; Cinar A; Turksoy K; Riddell MC
    Diabetes Technol Ther; 2017 Jun; 19(6):370-378. PubMed ID: 28613947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin Pump Malfunction During Hospitalization: Two Case Reports.
    Faulds ER; Wyne KL; Buschur EO; McDaniel J; Dungan K
    Diabetes Technol Ther; 2016 Jun; 18(6):399-403. PubMed ID: 27027151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Numerical and clinical precision of continuous glucose monitoring in Colombian patients treated with insulin infusion pump with automated suspension in hypoglycemia.
    Gómez AM; Marín Sánchez A; Muñoz OM; Colón Peña CA
    Endocrinol Nutr; 2015 Dec; 62(10):485-92. PubMed ID: 26531841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
    Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
    N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: a systematic review and meta-analysis of randomized-controlled trials.
    Fang Z; Liu M; Tao J; Li C; Zou F; Zhang W
    J Endocrinol Invest; 2022 Mar; 45(3):471-481. PubMed ID: 34535888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.